Mylan #39;s migraine The generic drug maker #39;s deal to buy King Pharmaceuticals was supposed to mark its arrival in the brand-name drug business. Instead, it put the spotlight on a new CEO #39;s strategy that billionaire investor Carl Icahn doesn #39;t like.